BG103793A - COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS - Google Patents

COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS

Info

Publication number
BG103793A
BG103793A BG103793A BG10379399A BG103793A BG 103793 A BG103793 A BG 103793A BG 103793 A BG103793 A BG 103793A BG 10379399 A BG10379399 A BG 10379399A BG 103793 A BG103793 A BG 103793A
Authority
BG
Bulgaria
Prior art keywords
hmg
bile acid
reductase inhibitors
combined therapy
benzothiapins
Prior art date
Application number
BG103793A
Other languages
Bulgarian (bg)
Inventor
Bradley Keller
Kevin Glenn
Robert Manning
Original Assignee
G.D.Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG103793(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G.D.Searle & Co filed Critical G.D.Searle & Co
Publication of BG103793A publication Critical patent/BG103793A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to benzothiapines, their derivatives and analogues, pharmaceutical compositions containing them and methods using these compounds and compositions in medicine, in particular for the prevention and treatement of hyperlipidemic conditions related to atherosclerosis or hypercholestirolemia in mammals. The invention also relates to compositions and methods for combined therapy making use of inhibitors of the ileal bile acid transport and HMG Co-A reductase inhibitors for the treatment of hyperlipidemic conditions. 17 claims
BG103793A 1997-03-11 1999-10-11 COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS BG103793A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4066097P 1997-03-11 1997-03-11
PCT/US1998/003792 WO1998040375A2 (en) 1997-03-11 1998-03-10 COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Publications (1)

Publication Number Publication Date
BG103793A true BG103793A (en) 2000-07-31

Family

ID=21912237

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103793A BG103793A (en) 1997-03-11 1999-10-11 COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS

Country Status (16)

Country Link
EP (1) EP0971744A2 (en)
JP (1) JP2002500628A (en)
CN (1) CN1255864A (en)
AU (1) AU730024C (en)
BG (1) BG103793A (en)
BR (1) BR9808013A (en)
CA (1) CA2283575A1 (en)
HU (1) HUP0002395A3 (en)
IL (1) IL131872A0 (en)
MX (1) MXPA99008417A (en)
NO (1) NO994390L (en)
NZ (1) NZ337830A (en)
PL (1) PL336415A1 (en)
RU (1) RU2247579C2 (en)
SK (1) SK125099A3 (en)
WO (1) WO1998040375A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AU2003241629B2 (en) * 1999-04-19 2005-06-16 Astrazeneca Ab An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (en) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002051396A1 (en) * 2000-12-26 2002-07-04 Sankyo Company, Limited Pharmaceutical compositions containing cyclobutene derivatives
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (en) 2001-09-08 2014-02-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2003053368A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
CA2497345C (en) * 2002-08-28 2008-10-14 Asahi Kasei Pharma Corporation Novel quaternary ammonium compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
CN1930137B (en) 2004-02-27 2011-07-20 旭化成制药株式会社 Novel benzothiazepine and benzothiepine compounds
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
MX345040B (en) 2010-11-08 2017-01-16 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder.
RS60901B1 (en) 2010-11-08 2020-11-30 Albireo Ab Ibat inhibitors for the treatment of liver diseases
CN104023727B (en) 2011-10-28 2017-04-05 鲁美纳医药公司 For treating the bile acid recycling inhibitors of children's cholestatic liver disease
CN104023718B (en) 2011-10-28 2017-04-05 鲁美纳医药公司 For treating the bile acid recycling inhibitors of high cholemia and cholestatic liver disease
AU2014228850A1 (en) 2013-03-15 2015-10-29 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
CN106794188B (en) * 2014-09-28 2022-12-02 华辉安健（北京）生物科技有限公司 Polymeric bile acid derivatives inhibit hepatitis B and delta virus and NTCP trafficking
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601744B (en) 2016-02-09 2022-01-04 阿尔比里奥公司 Oral cholestyramine formulations and uses thereof
RU2750937C2 (en) 2016-02-09 2021-07-06 Альбирео Аб Oral cholestyramine composition and application thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
JP7328207B2 (en) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ Cholestyramine pellets, oral cholestyramine preparations, and their uses
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7391048B2 (en) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
FI3921028T3 (en) 2019-02-06 2023-01-31 Benzothiadiazepine compounds and their use as bile acid modulators
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP2022520121A (en) 2019-02-12 2022-03-28 ミルム ファーマシューティカルズ インコーポレイテッド How to treat cholestasis
CN114786772B (en) 2019-12-04 2024-04-09 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
TW202134221A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504645A (en) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134218A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothiazepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134222A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023537285A (en) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN112274648B (en) * 2020-11-23 2022-10-14 郑州大学 Preparation method of cholesterol oxidase modified hybrid metal organic framework tumor targeting nano preparation
JP2024500309A (en) 2020-12-04 2024-01-09 アルビレオ エービー Benzothia(di)azepine compounds and their use as bile acid modulators
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
TW202423921A (en) * 2022-08-22 2024-06-16 美商安塔製藥公司 Fused heterobicyclic antiviral agents

Also Published As

Publication number Publication date
AU730024B2 (en) 2001-02-22
AU6440898A (en) 1998-09-29
IL131872A0 (en) 2001-03-19
MXPA99008417A (en) 2005-02-03
EP0971744A2 (en) 2000-01-19
RU2247579C2 (en) 2005-03-10
HUP0002395A3 (en) 2002-12-28
NO994390D0 (en) 1999-09-10
CN1255864A (en) 2000-06-07
JP2002500628A (en) 2002-01-08
NZ337830A (en) 2001-07-27
WO1998040375A3 (en) 1998-12-03
CA2283575A1 (en) 1998-09-17
BR9808013A (en) 2001-09-25
WO1998040375A2 (en) 1998-09-17
AU730024C (en) 2004-08-05
SK125099A3 (en) 2001-02-12
NO994390L (en) 1999-11-04
PL336415A1 (en) 2000-06-19
HUP0002395A2 (en) 2001-05-28

Similar Documents

Publication Publication Date Title
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
GR3035583T3 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
AP2001002062A0 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake.
HK1025737A1 (en) Treatment of multiple sclerosis through ingestion of copolymer-1
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
EP1021177A4 (en) Compositions and methods for prevention and treatment of vascular degenerative diseases
IL108007A (en) USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
EP2138170A3 (en) Prevention and Treatment of Oxidative Stress Disorders by compounds which elevate intracellular levels of glutathione or Phase II Detoxification Enzymes
TW268937B (en)
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
EP0705100A4 (en) Therapeutic substituted guanidines
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
MX9606503A (en) Pla2 inhibitors and their use for inhibition of intestinal cholesterol absorption.
HK1009325A1 (en) Composition comprising l-carnitine or acyl-l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
ES2065855A1 (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
DK0852469T3 (en) Use of threonine in the treatment of phenylketonuria
IL113076A (en) Pharmaceutical hypocholesterolemic and hypotriglyceridemic compositions containing tricyclic dipeptide derivatives of alpha-(aminoalkanoylthio) benzenepropionic acid
ES2058025A1 (en) Application of phytic acid and/or its phytates in pathological and prepathological conditions derived from renal oxalocalcic idiopathic lithiasis
HUP9702369A3 (en) Pharmaceutical composition of natural active components for treating kinetose